Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Elliott, A. J. Articles by Roy-Byrne, P. P. Search for Related Content PubMed Citation Articles by Elliott, A. J. Articles by Roy-Byrne, P. P.

Randomized, Placebo-Controlled Trial of Paroxetine Versus Imipramine in Depressed HIV-Positive Outpatients

OBJECTIVE: This study examined whether a selective serotonin reuptake inhibitor (paroxetine) had comparable efficacy but greater tolerability than a tricyclic antidepressant (imipramine) in depressed patients with HIV infection. METHOD: Seventy-five HIV-positive patients (45% of whom had AIDS) were blindly and randomly assigned to receive paroxetine (N=25), imipramine (N=25), or placebo (N=25) in a 12-week trial. The Hamilton Anxiety Rating Scale, the Hamilton Depression Rating Scale, the Clinical Global Impression scale, and the SAFETEE general inquiry (for safety and tolerability) were administered at weeks 2, 4, 6, 8, and 12. RESULTS: Fifty-six (75%) of the 75 patients completed 6 weeks and 34 (45%) completed 12 weeks of the trial. The mean daily doses of both paroxetine (33.9 mg) and imipramine (162.5 mg) were significantly more effective than placebo; they were comparably effective at weeks 6, 8, and 12 according to the intent-to-treat analysis and at week 8 according to the analysis for the subjects who completed the trial (for them, only imipramine was superior to placebo at week 12). There were significantly more dropouts due to side effects from imipramine (48%) than from both paroxetine (20%) and placebo (24%). CONCLUSIONS: Depressed patients with HIV infection responded to imipramine or paroxetine at a higher rate than to placebo irrespective of severity of immunosuppression. Because paroxetine was much better tolerated than imipramine, its overall effectiveness may be greater. However, because of the small study group and the high attrition rate, these findings cannot be generalized and may need replication in a larger study group.

This article has been cited by other articles:

				G. Gartlehner, B. N. Gaynes, R. A. Hansen, P. Thieda, A. DeVeaugh-Geiss, E. E. Krebs, C. G. Moore, L. Morgan, and K. N. Lohr Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians Ann Intern Med, November 18, 2008; 149(10): 734 - 750. [Abstract] [Full Text] [PDF]

				M. J. Repetto and J. M. Petitto Psychopharmacology in HIV-Infected Patients Psychosom Med, June 1, 2008; 70(5): 585 - 592. [Abstract] [Full Text] [PDF]

				S. D. Block and for the American College of Physicians-American So Assessing and Managing Depression in the Terminally Ill Patient Focus, April 1, 2005; 3(2): 310 - 319. [Abstract] [Full Text] [PDF]

				J. Caballero and M. C Nahata Use of Selective Serotonin-Reuptake Inhibitors in the Treatment of Depression in Adults with HIV Ann. Pharmacother., January 1, 2005; 39(1): 141 - 145. [Abstract] [Full Text] [PDF]

				M. B. Currier, G. Molina, and M. Kato Citalopram Treatment of Major Depressive Disorder in Hispanic HIV and AIDS Patients: A Prospective Study Psychosomatics, June 1, 2004; 45(3): 210 - 216. [Abstract] [Full Text] [PDF]

				M. B. Currier, G. Molina, and M. Kato A Prospective Trial of Sustained-Release Bupropion for Depression in HIV-Seropositive and AIDS Patients Psychosomatics, April 1, 2003; 44(2): 120 - 125. [Abstract] [Full Text] [PDF]

				B. Vitiello, M. A. Burnam, E. G. Bing, R. Beckman, and M. F. Shapiro Use of Psychotropic Medications Among HIV-Infected Patients in the United States Am J Psychiatry, March 1, 2003; 160(3): 547 - 554. [Abstract] [Full Text] [PDF]

				G. P. Overman and S. L. Anderson Depression among Patients with HIV/AIDS: A Treatment Dilemma Journal of Pharmacy Practice, December 1, 2001; 14(6): 540 - 550. [Abstract] [PDF]

				Psychiatric Aspects of HIV Care AIDS Clinical Care, November 1, 2001; 2001(1101): 6 - 6. [Full Text]

				J. R. Ickovics, M. E. Hamburger, D. Vlahov, E. E. Schoenbaum, P. Schuman, R. J. Boland, J. Moore, and for the HIV Epidemiology Research Study Group Mortality, CD4 Cell Count Decline, and Depressive Symptoms Among HIV-Seropositive Women: Longitudinal Analysis From the HIV Epidemiology Research Study JAMA, March 21, 2001; 285(11): 1466 - 1474. [Abstract] [Full Text] [PDF]

				S. D. Block and for the ACP-ASIM End-of-Life Care Consensus Panel Assessing and Managing Depression in the Terminally Ill Patient Ann Intern Med, February 1, 2000; 132(3): 209 - 218. [Abstract] [Full Text] [PDF]

				J. G. Rabkin, G. J. Wagner, and R. Rabkin Fluoxetine Treatment for Depression in Patients With HIV and AIDS: A Randomized, Placebo-Controlled Trial Am J Psychiatry, January 1, 1999; 156(1): 101 - 107. [Abstract] [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 1998 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us